Detailed information for compound 315003

Basic information

Technical information
  • TDR Targets ID: 315003
  • Name: 4-benzyl-1-(3,4-dihydro-2H-chromen-2-ylmethyl )piperidine
  • MW: 321.456 | Formula: C22H27NO
  • H donors: 0 H acceptors: 0 LogP: 5.09 Rotable bonds: 4
    Rule of 5 violations (Lipinski): 1
  • SMILES: c1ccc(cc1)CC1CCN(CC1)CC1CCc2c(O1)cccc2
  • InChi: 1S/C22H27NO/c1-2-6-18(7-3-1)16-19-12-14-23(15-13-19)17-21-11-10-20-8-4-5-9-22(20)24-21/h1-9,19,21H,10-17H2
  • InChiKey: XIEPNNMDKPLLAY-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 4-benzyl-1-(chroman-2-ylmethyl)piperidine
  • 4-benzyl-1-(3,4-dihydro-2H-1-benzopyran-2-ylmethyl)piperidine
  • 1-(3,4-dihydro-2H-chromen-2-ylmethyl)-4-(phenylmethyl)piperidine
  • 1-(chroman-2-ylmethyl)-4-(phenylmethyl)piperidine
  • 1-(2-chromanylmethyl)-4-(phenylmethyl)piperidine
  • 4-(benzyl)-1-(chroman-2-ylmethyl)piperidine

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Rattus norvegicus Dopamine D2 receptor Starlite/ChEMBL References
Homo sapiens 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled Starlite/ChEMBL References
Homo sapiens sigma non-opioid intracellular receptor 1 Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Candida albicans sterol C8-C7 isomerase Get druggable targets OG5_131051 All targets in OG5_131051
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_131051 All targets in OG5_131051
Echinococcus granulosus biogenic amine 5HT receptor Get druggable targets OG5_133249 All targets in OG5_133249
Echinococcus multilocularis serotonin receptor Get druggable targets OG5_133249 All targets in OG5_133249
Leishmania major C-8 sterol isomerase-like protein Get druggable targets OG5_131051 All targets in OG5_131051
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_131051 All targets in OG5_131051
Schistosoma japonicum expressed protein Get druggable targets OG5_133249 All targets in OG5_133249
Echinococcus multilocularis serotonin receptor Get druggable targets OG5_133249 All targets in OG5_133249
Trypanosoma congolense C-8 sterol isomerase, putative Get druggable targets OG5_131051 All targets in OG5_131051
Trypanosoma brucei C-8 sterol isomerase, putative Get druggable targets OG5_131051 All targets in OG5_131051
Leishmania mexicana C-8 sterol isomerase-like protein Get druggable targets OG5_131051 All targets in OG5_131051
Trypanosoma cruzi C-8 sterol isomerase, putative Get druggable targets OG5_131051 All targets in OG5_131051
Leishmania braziliensis C-8 sterol isomerase-like protein Get druggable targets OG5_131051 All targets in OG5_131051
Trypanosoma brucei gambiense C-8 sterol isomerase, putative Get druggable targets OG5_131051 All targets in OG5_131051
Schistosoma japonicum ko:K04153 5-hydroxytryptamine (serotonin) receptor 1A, putative Get druggable targets OG5_133249 All targets in OG5_133249
Brugia malayi ERG2 and Sigma1 receptor like protein Get druggable targets OG5_131051 All targets in OG5_131051
Leishmania infantum C-8 sterol isomerase-like protein Get druggable targets OG5_131051 All targets in OG5_131051
Candida albicans sterol C8-C7 isomerase Get druggable targets OG5_131051 All targets in OG5_131051
Schistosoma mansoni biogenic amine (5HT) receptor Get druggable targets OG5_133249 All targets in OG5_133249
Leishmania donovani C-8 sterol isomerase-like protein Get druggable targets OG5_131051 All targets in OG5_131051
Trypanosoma congolense C-8 sterol isomerase, putative Get druggable targets OG5_131051 All targets in OG5_131051
Schistosoma japonicum Octopamine receptor, putative Get druggable targets OG5_133249 All targets in OG5_133249
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_133249 All targets in OG5_133249
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_133249 All targets in OG5_133249
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Schistosoma mansoni muscarinic acetylcholine (GAR) receptor Dopamine D2 receptor   444 aa 487 aa 23.8 %
Schistosoma mansoni amine GPCR Dopamine D2 receptor   444 aa 424 aa 32.1 %
Echinococcus multilocularis serotonin receptor Dopamine D2 receptor   444 aa 428 aa 31.3 %
Schistosoma japonicum ko:K04207 neuropeptide Y receptor Y5, putative Dopamine D2 receptor   444 aa 386 aa 19.7 %
Echinococcus granulosus g protein coupled receptor Dopamine D2 receptor   444 aa 457 aa 21.0 %
Onchocerca volvulus Dopamine D2 receptor   444 aa 418 aa 23.0 %
Schistosoma mansoni biogenic amine (dopamine) receptor Dopamine D2 receptor   444 aa 494 aa 26.3 %
Schistosoma mansoni biogenic amine receptor Dopamine D2 receptor   444 aa 452 aa 30.1 %
Onchocerca volvulus Glycoprotein hormone beta 5 homolog Dopamine D2 receptor   444 aa 476 aa 24.2 %
Schistosoma japonicum Octopamine receptor, putative Dopamine D2 receptor   444 aa 456 aa 29.4 %
Echinococcus granulosus biogenic amine 5HT receptor Dopamine D2 receptor   444 aa 429 aa 31.7 %
Echinococcus multilocularis g protein coupled receptor Dopamine D2 receptor   444 aa 465 aa 21.5 %
Onchocerca volvulus RB1-inducible coiled-coil protein 1 homolog Dopamine D2 receptor   444 aa 474 aa 23.4 %
Schistosoma japonicum ko:K04136 adrenergic receptor, alpha 1b, putative Dopamine D2 receptor   444 aa 440 aa 30.0 %
Loa Loa (eye worm) hypothetical protein Dopamine D2 receptor   444 aa 433 aa 21.2 %
Schistosoma japonicum ko:K04145 dopamine receptor D2, putative Dopamine D2 receptor   444 aa 432 aa 30.8 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Loa Loa (eye worm) hypothetical protein 0.0153 0.1525 0.1525
Plasmodium vivax bifunctional dihydrofolate reductase-thymidylate synthase, putative 0.0269 0.491 0.5
Loa Loa (eye worm) dihydrofolate reductase 0.0269 0.491 0.491
Echinococcus granulosus dihydrofolate reductase 0.0269 0.491 1
Loa Loa (eye worm) hypothetical protein 0.0227 0.3687 0.3687
Mycobacterium tuberculosis Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) 0.0269 0.491 0.5
Schistosoma mansoni dihydrofolate reductase 0.0269 0.491 1
Chlamydia trachomatis dihydrofolate reductase 0.0269 0.491 0.5
Trypanosoma cruzi C-8 sterol isomerase, putative 0.0445 1 1
Echinococcus multilocularis dihydrofolate reductase 0.0269 0.491 1
Trypanosoma brucei C-8 sterol isomerase, putative 0.0445 1 1
Mycobacterium leprae DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) 0.0269 0.491 0.5
Brugia malayi dihydrofolate reductase family protein 0.0269 0.491 0.491
Brugia malayi Dihydrofolate reductase 0.0269 0.491 0.491
Plasmodium falciparum bifunctional dihydrofolate reductase-thymidylate synthase 0.0269 0.491 0.5
Leishmania major C-8 sterol isomerase-like protein 0.0445 1 1
Mycobacterium ulcerans dihydrofolate reductase DfrA 0.0269 0.491 0.5
Loa Loa (eye worm) hypothetical protein 0.0153 0.1525 0.1525
Toxoplasma gondii bifunctional dihydrofolate reductase-thymidylate synthase 0.0269 0.491 0.5
Loa Loa (eye worm) hypothetical protein 0.0445 1 1

Activities

Activity type Activity value Assay description Source Reference
Emax (functional) = 61.9 % Maximal stimulation achieved towards 5-hydroxytryptamine 1A receptor is determined by measuring relative intrinsic activity in the [35S]-GTPAS binding assay ChEMBL. 15634021
Emax (functional) = 61.9 % Maximal stimulation achieved towards 5-hydroxytryptamine 1A receptor is determined by measuring relative intrinsic activity in the [35S]-GTPAS binding assay ChEMBL. 15634021
Inhibition (binding) = 975 % Percentage inhibition of dopamine D2 receptor at 10 uM concentration using 0.2 nM [3H]-spiperone ChEMBL. 15634021
Inhibition (binding) = 975 % Percentage inhibition of dopamine D2 receptor at 10 uM concentration using 0.2 nM [3H]-spiperone ChEMBL. 15634021
Ki (binding) = 3.61 nM Inhibitory constant against Dopamine receptor D2 ChEMBL. 15634021
Ki (binding) = 3.61 nM Inhibitory constant against Dopamine receptor D2 ChEMBL. 15634021
Ki (binding) = 4.8 nM Inhibitory constant against sigma receptor type 2 using 3 nM [3H]-ditolylguanidine ChEMBL. 15634021
Ki (binding) = 4.8 nM Inhibitory constant against sigma receptor type 2 using 3 nM [3H]-ditolylguanidine ChEMBL. 15634021
Ki (binding) = 11.5 nM Inhibitory constant was determined against 5-hydroxytryptamine 1A receptor using 1.2 nM [3H]-8-OH-DPAT ChEMBL. 15634021
Ki (binding) = 11.5 nM Inhibitory constant was determined against 5-hydroxytryptamine 1A receptor using 1.2 nM [3H]-8-OH-DPAT ChEMBL. 15634021
Ki (binding) = 11.6 nM Inhibitory constant against sigma receptor type 1 using 3 nM [3H]-pentazocine ChEMBL. 15634021
Ki (binding) = 11.6 nM Inhibitory constant against sigma receptor type 1 using 3 nM [3H]-pentazocine ChEMBL. 15634021
Ki (binding) = 924 nM Inhibitory constant against dopamine D2 receptor using 0.2 nM [3H]-spiperone ChEMBL. 15634021
Ki (binding) = 924 nM Inhibitory constant against dopamine D2 receptor using 0.2 nM [3H]-spiperone ChEMBL. 15634021
pD2 (functional) = 7.89 Potency towards 5-hydroxytryptamine 1A receptor was determined using [35S]-GTPAS binding Assay ChEMBL. 15634021
Ratio (binding) = 0.4 Ratio of Ki against Sigma receptor type 1 and 2 ChEMBL. 15634021
Ratio (binding) = 0.4 Ratio of Ki against Sigma receptor type 1 and 2 ChEMBL. 15634021

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.